Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel potassium channel inhibitors

An alkyl and compound technology, applied in the field of new compounds, can solve problems such as poor solubility and achieve the effect of high solubility

Pending Publication Date: 2021-11-09
SANIONA
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0027] Many known potassium channel modulators have poor solubility in water

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel potassium channel inhibitors
  • Novel potassium channel inhibitors
  • Novel potassium channel inhibitors

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0304] Preparation of compounds

[0305] It may be (e.g., according to those in the working examples) were prepared according to any conventional chemical synthesis methods known to those skilled in the compounds according to the invention. Starting material for the method of the present application are known or can be readily prepared from commercially available chemicals by conventional methods known to the skilled person.

[0306] The final product of the reaction described herein can be separated by conventional techniques such as extraction, crystallization, distillation, chromatography, or the like.

[0307] The compounds of the invention may be present in a non-solvated form and a solvated form of a pharmaceutically acceptable solvent such as water, ethanol, or the like. Typically, for the purposes of the present invention, the solvate form is considered to be equivalent to the non-solventized form.

[0308] Pharmaceutical composition

[0309] The invention also relates to a...

Embodiment 1

[0627] Example [1] -N- (2- (dimethylamino) ethyl) -N- (1- (4-fluoro-3- (trifluoromethyl) phenyl) cyclopropyl) Methyl carbamate

[0628] step 1

[0629] The addition of 4-fluorine-3- (trifluoromethyl) benzoitrile (105.75 mmol) and isopropyl alcohol (IV) (116.33 mmol) in a solution of titanium (IV) (116.33 mmol) in dry ether in the ether in the ether. Based magnesium bromide 3M solution (222.09 mmol). The resulting yellow solution was stirred for 10 minutes and was slowly warmed to room temperature by 4h. Then, a trifluoride ethyl ether compound (211.51 mmol) was added and the reaction mixture was stirred at room temperature for 24 h. The reaction mixture was quenched with a 1.5 N HCl solution and extracted with ethyl acetate. The aqueous phase was alkated with a 10% sodium hydroxide solution and extracted with ethyl acetate. The organic layer was washed with brine and dried over anhydrous sodium sulfate to obtain a crude product: 10% TEA in acetate: petroleum ether was purified b...

Embodiment 2

[0634] Example [2] - (2-amino-2-methylpropyl) (1- (4-fluoro-3- (trifluoromethyl) phenyl) cyclopropyl) amino Sourmethyl

[0635] step 1

[0636] Diamparten oxidants were added to Solution of tert-butyl (20 g, 105.7 mmol) in dichloromethane (100 mL) at 0 ° C (1-hydroxy-2-methylpropylene)). Martin Periodinane (55.4 g, 126.8 mmol) and stirred at room temperature for 16 h. The reaction mixture was filtered and the filtrate was extracted with dichloromethane to wash with a saturated thiosulfate solution and 10% sodium bicarbonate solution. The organic layer was dried over sodium sulfate, filtered and dried under vacuum to give the crude product, and the ethyl acetate in petroleum ether was purified as a solvent to give a white solid (2-methyl-1). - oxo-2-yl) of tert-butyl ester [2.1] (19.5 g, 99%).

[0637] Step 2

[0638]To 1- (4-fluoro-3- (trifluoromethyl) phenyl) cyclopropylene-1-amine [1.1] (0.22 mmol) in IPA (5 mL) in IPA (5 mL) at 0 ° C Titcharide (2-methyl-1-oxpropan-2-yl) carb...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to novel compounds, pharmaceutical compositions comprising such compounds and their use for treating, alleviating or preventing diseases or disorders relating to the activity of potassium channels.

Description

Technical field [0001] The present invention relates to a novel compound comprising a pharmaceutical composition comprising such a compound and a disease or disorder for treating, alleviating or preventing an activity associated with potassium channel activity. Background technique [0002] The ion channel is a transmembrane protein that catalyzes the transport of inorganic ions across the cell membrane. The ion channel involves a very variety of processes, including the production of action potentials and timing, synaptic transfer, secretion of hormones, and contraction of muscle. [0003] All mammalian cells express potassium in its cell membranes (K + The channel, and the channel is dominated in the regulating film potential. In nerve and muscle cells, they affect the form of action potential, the frequency and discharge mode of the action potential, the release of neurotransmitter, and the degree of bump expansion and blood vessels. In non-excited cells, k + Channel regulatin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D205/04C07C233/62C07D265/30C07D207/09C07D213/61A61P1/00A61K31/132C07C211/40A61K31/18A61K31/27A61K31/397A61K31/4025A61K31/44C07C271/24C07C311/07
CPCC07C211/40C07C233/62C07C271/24C07C311/07C07D205/04C07D207/09C07D213/61C07D265/30A61P1/00C07C2601/02A61P29/00A61P11/00
Inventor D·T·布朗P·克里斯托弗森T·A·雅各布森J·S·拉森P·H·鲍尔森D·斯特罗克
Owner SANIONA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com